Free beta — full access, free until October 2026. No card, no auto-charge — paid plans are opt-in when they launch.
Company
MYRIAD GENETICS INC (MYGN)
Standardized SEC financial data for MYRIAD GENETICS INC — income statement, balance sheet, cash flow and 40+ ratios, available as a clean JSON API. CIK 0000899923 · NASDAQ · In Vitro & In Vivo Diagnostic Substances.
Income statement
USD
FY2020
FY2021
FY2022
FY2023
FY2024
FY2025
Revenue
$638.6M
$690.6M
$678.4M
$753.2M
$837.6M
$824.5M
Cost of revenue
—
—
$202.0M
$236.2M
$252.2M
$247.9M
Gross profit
—
—
$476.4M
$517.0M
$585.4M
$576.6M
R&D expense
$77.2M
$81.9M
$85.4M
$88.7M
$113.4M
$106.8M
SG&A expense
$507.3M
$537.8M
$514.7M
$572.9M
$284.1M
$280.8M
Operating income
-$231.7M
-$190.5M
-$140.6M
-$257.4M
-$123.5M
-$387.2M
EBITDA
-$159.7M
-$127.7M
-$87.9M
-$195.5M
-$62.3M
-$333.5M
Interest expense
$10.8M
$6.6M
$3.2M
$2.9M
$1.9M
$8.4M
Pretax income
-$223.3M
-$57.1M
-$140.6M
-$262.2M
-$123.5M
-$395.1M
Income tax
$23.7M
$29.9M
$28.6M
$1.1M
$3.8M
$29.2M
Net income
-$199.5M
-$27.2M
-$112.0M
-$263.3M
-$127.3M
-$365.9M
EPS (diluted)
$-2.69
$-0.35
$-1.39
$-3.18
$-1.41
$-3.95
Standardized from MYRIAD GENETICS INC's SEC filings — per-share figures split-adjusted. Full history via the API.